Olema Pharmaceuticals (OLMA) Total Liabilities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Total Liabilities data on file, last reported at $50.2 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $50.2 million, up 91.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.2 million (up 91.57% YoY), and the FY2025 annual result was $54.9 million, up 30.6% from the prior year.
• Total Liabilities fell to $50.2 million in Q1 2026 per OLMA's latest filing, from $54.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $54.9 million in Q4 2025 and troughed at $12.3 million in Q1 2022.
• A 5-year average of $28.1 million and a median of $26.2 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 133.62% in 2022, then decreased 4.34% in 2025.
• A 5-year view of Total Liabilities shows it stood at $18.1 million in 2022, then advanced by 27.36% to $23.0 million in 2023, then surged by 82.28% to $42.0 million in 2024, then surged by 30.6% to $54.9 million in 2025, then slipped by 8.57% to $50.2 million in 2026.
• Business Quant data shows OLMA's Total Liabilities at $50.2 million in Q1 2026, $54.9 million in Q4 2025, and $45.0 million in Q3 2025.